Boston Scientific is a medical devices business based in the US. Boston Scientific shares (BSX) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $95.12 – an increase of 1.55% over the previous week. Boston Scientific employs 53,000 staff and has a trailing 12-month revenue of around $16.7 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $95.12 |
|---|---|
| 52-week range | $66.80 - $107.17 |
| 50-day moving average | $100.16 |
| 200-day moving average | $89.39 |
| Wall St. target price | $114.94 |
| PE ratio | 76.096 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $95.12 from 2025-04-17
| 1 week (2025-04-11) | 1.55% |
|---|---|
| 1 month (2025-03-20) | -6.29% |
| 3 months (2025-01-17) | -3.59% |
| 6 months (2024-10-18) | 8.00% |
| 1 year (2024-04-19) | 41.27% |
|---|---|
| 2 years (2023-04-19) | 79.84% |
| 3 years (2022-04-19) | 108.05% |
| 5 years (2020-04-17) | 148.42% |
Valuing Boston Scientific stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Boston Scientific's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Boston Scientific's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 76x. In other words, Boston Scientific shares trade at around 76x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Boston Scientific's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8698. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Boston Scientific's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Boston Scientific's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.3 billion.
The EBITDA is a measure of a Boston Scientific's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.7 billion |
|---|---|
| Operating margin TTM | 17.32% |
| Gross profit TTM | $11.5 billion |
| Return on assets TTM | 5.04% |
| Return on equity TTM | 8.89% |
| Profit margin | 11.07% |
| Book value | $14.76 |
| Market Capitalization | $140.7 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Boston Scientific.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Boston Scientific's overall score of 29.23 (as at 12/31/2018) is nothing to write home about – landing it in it in the 57th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Boston Scientific is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.51/100
Social score: 12.87/100
Governance score: 7.87/100
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Boston Scientific scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Boston Scientific hasn't always managed to keep its nose clean.
Boston Scientific Corp was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.23 |
|---|---|
| Total ESG percentile | 56.94 |
| Environmental score | 1.51 |
| Social score | 12.87 |
| Governance score | 7.87 |
| Level of controversy | 3 |
We're not expecting Boston Scientific to pay a dividend over the next 12 months.
Boston Scientific's shares were split on a 2:1 basis on 5 November 2003 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Boston Scientific shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Boston Scientific shares which in turn could have impacted Boston Scientific's share price.
Over the last 12 months, Boston Scientific's shares have ranged in value from as little as $66.8 up to $107.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Boston Scientific's is 0.731. This would suggest that Boston Scientific's shares are less volatile than average (for this exchange).
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.